Arecor Therapeutics plc (AREC) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the Arecor Therapeutics plc investor presentation. Throughout this quarter presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time via the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. Before we begin, I'd like to make the following poll. And I'd to hand you over to the executive management team from Arecor Therapeutics plc. Sarah, good morning. Thank you. Good morning. Good morning, everybody. Thank you for taking the time to join us today. So name is Doctor Sarah Howell. I'm the CEO of Arecor Therapeutics, and I'm joined today by David Ellen, our CFO, who will be talking you through the full year results until 12/31/2025. So our customary legal notice. So at Arecor, we're very much focused just as a quick recap. We're a clinical stage biotech company, as you know. We're focused on developing superior therapeutics that can reduce treatment burden and improve outcomes, specifically for people living with diabetes, obesity, and other cardiometabolic diseases. Our focus is very much on two core product areas being in the diabetes space and the oral delivery of peptides. And these are areas where there's significant unmet patient need that we're aiming to address with our superior products in high end and billion dollar growth markets. So our lead program is our best in class insulin, a t two seven eight. So this is the only ultra concentrated, ultra rapid acting insulin in development, and it's been specifically designed with this profile for use in next generation automated insulin delivery systems. And I'll I'll talk a little bit more just as a a reminder around what we need by automated insulin delivery system, and I'll re...